Literature DB >> 28756524

Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration.

Mohamed Attia1,2,3, Marie Maurer1,2,3, Marieke Robinet1,2,3, Fabien Le Grand1,2,3, Elie Fadel4, Rozen Le Panse1,2,3, Gillian Butler-Browne1,2,3, Sonia Berrih-Aknin5,6,7.   

Abstract

Myasthenia gravis (MG) is a neuromuscular disease caused in most cases by anti-acetyl-choline receptor (AChR) autoantibodies that impair neuromuscular signal transmission and affect skeletal muscle homeostasis. Myogenesis is carried out by muscle stem cells called satellite cells (SCs). However, myogenesis in MG had never been explored. The aim of this study was to characterise the functional properties of myasthenic SCs as well as their abilities in muscle regeneration. SCs were isolated from muscle biopsies of MG patients and age-matched controls. We first showed that the number of Pax7+ SCs was increased in muscle sections from MG and its experimental autoimmune myasthenia gravis (EAMG) mouse model. Myoblasts isolated from MG muscles proliferate and differentiate more actively than myoblasts from control muscles. MyoD and MyoG were expressed at a higher level in MG myoblasts as well as in MG muscle biopsies compared to controls. We found that treatment of control myoblasts with MG sera or monoclonal anti-AChR antibodies increased the differentiation and MyoG mRNA expression compared to control sera. To investigate the functional ability of SCs from MG muscle to regenerate, we induced muscle regeneration using acute cardiotoxin injury in the EAMG mouse model. We observed a delay in maturation evidenced by a decrease in fibre size and MyoG mRNA expression as well as an increase in fibre number and embryonic myosin heavy-chain mRNA expression. These findings demonstrate for the first time the altered function of SCs from MG compared to control muscles. These alterations could be due to the anti-AChR antibodies via the modulation of myogenic markers resulting in muscle regeneration impairment. In conclusion, the autoimmune attack in MG appears to have unsuspected pathogenic effects on SCs and muscle regeneration, with potential consequences on myogenic signalling pathways, and subsequently on clinical outcome, especially in the case of muscle stress.

Entities:  

Keywords:  AChR antibodies; Experimental autoimmune myasthenia gravis (EAMG); MG patients; Myogenic factors

Mesh:

Substances:

Year:  2017        PMID: 28756524     DOI: 10.1007/s00401-017-1754-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  12 in total

1.  The first year.

Authors:  Johannes Attems
Journal:  Acta Neuropathol       Date:  2019-12-12       Impact factor: 17.088

Review 2.  Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.

Authors:  Gerben J Schaaf; Rodrigo Canibano-Fraile; Tom J M van Gestel; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

4.  MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway.

Authors:  Kai-Yi Song; Xiu-Ming Guo; Hui-Qi Wang; Lei Zhang; Si-Yuan Huang; Ying-Chao Huo; Gang Zhang; Jin-Zhou Feng; Rong-Rong Zhang; Yue Ma; Qing-Zhe Hu; Xin-Yue Qin
Journal:  Cell Death Dis       Date:  2020-07-18       Impact factor: 8.469

5.  Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease.

Authors:  Gerben J Schaaf; Tom J M van Gestel; Stijn L M In 't Groen; Bart de Jong; Björn Boomaars; Antonietta Tarallo; Monica Cardone; Giancarlo Parenti; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Acta Neuropathol Commun       Date:  2018-11-07       Impact factor: 7.801

6.  MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease.

Authors:  Samir R Nath; Matthew L Lieberman; Zhigang Yu; Caterina Marchioretti; Samuel T Jones; Emily C E Danby; Kate M Van Pelt; Gianni Sorarù; Diane M Robins; Gillian P Bates; Maria Pennuto; Andrew P Lieberman
Journal:  Acta Neuropathol       Date:  2020-04-18       Impact factor: 17.088

Review 7.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

8.  Functional skeletal muscle constructs from transdifferentiated human fibroblasts.

Authors:  Bin Xu; Allison Siehr; Wei Shen
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

Review 9.  Neuromuscular Development and Disease: Learning From in vitro and in vivo Models.

Authors:  Zachary Fralish; Ethan M Lotz; Taylor Chavez; Alastair Khodabukus; Nenad Bursac
Journal:  Front Cell Dev Biol       Date:  2021-10-27

10.  Upregulation of circ-FBL promotes myogenic proliferation in myasthenia gravis by regulation of miR-133/PAX7.

Authors:  Xiaoyin Lai; Zhuajin Bi; Xuelian Yang; Rongguo Hu; Lu Wang; Mingming Jin; Longxuan Li; Bitao Bu
Journal:  Cell Biol Int       Date:  2021-08-07       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.